PharmaTher Holdings Ltd. (OTCQB: PHRRF) is reshaping its business around MEDBOTX™, a robotic 3D‑printing platform designed to produce personalized medicines directly at the point of care….
Eli Lilly and Company (NYSE: LLY) is making a major push back into vaccines, signing deals worth up to 3.8 billion dollars to acquire three…
Jupiter Neurosciences (NASDAQ: JUNS) has jumped back onto investor watchlists after announcing a term sheet for exclusive U.S. rights to ALA‑002, a next‑generation MDMA therapeutic,…
Incyte’s (NASDAQ: INCY) new AI collaboration essentially gives shareholders a leveraged bet on making its R&D engine faster, cheaper, and more productive, with Genesis Molecular…
PharmAla Biotech’s (OTCQB: MDXXF) new licensing term sheet with Jupiter Neurosciences (NASDAQ: JUNS) gives Jupiter a differentiated MDMA‑based CNS asset while providing PharmAla with upfront…
Adial Pharmaceuticals (NASDAQ: ADIL) is having a strong session, with the stock up 18.32% to $1.905 after opening at $1.64 and trading between a day low of $1.64 and day high of…
Hepion Pharmaceuticals, Inc. (OTCQB: HEPA) is catching another speculative pop today, with the stock up 35.75% to $0.06 after opening at $0.0531 and trading between a day low of $0.0531 and a day high of…
Bayer (BAYN.DE) is acquiring privately held Perfuse Therapeutics in a transaction worth up to 2.45 billion dollars to expand and modernize its ophthalmology pipeline. The…
Axsome Therapeutics (NASDAQ: AXSM) announced that the U.S. Food and Drug Administration has approved Auvelity (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated…
Hepion Pharmaceuticals, Inc. (OTC: HEPA) is catching a speculative bid again, with shares up 31.24% at $0.071 after opening at $0.054, tagging a day high of $0.071 against a day low of $0.054. The…
April 29, 2026
Adial Pharmaceuticals Files New Patent Application To Extend AD04 Protection Toward 2045
What Adial just announced Adial Pharmaceuticals (NASDAQ: ADIL), has filed a new U.S. utility patent application for its lead drug candidate AD04. AD04 is a…
April 29, 2026
Silo Pharma’s PTSD Program Aligns With Federal Push To Fast‑Track Psychedelic Therapies
Silo Pharma (NASDAQ: SILO) is highlighting progress in its post‑traumatic stress disorder (PTSD) program as U.S. regulators move faster on psychedelic‑based mental health treatments. A recent…